Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid H...
October 23 2017 - 7:00AM
Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today presented
preclinical results for MGL-3196 in a poster session at The Liver
Meeting® 2017, American Association for the Study of Liver
Diseases (AASLD) being held at the Walter E. Washington
Convention Center in Washington, DC, October 20 –
24, 2017.
MGL-3196 is a first-in-class, oral, once-daily, liver-directed,
thyroid hormone receptor (THR) β-selective agonist medication that
is in Phase 2 development as a treatment for non-alcoholic
steatohepatitis (NASH) and heterozygous familial
hypercholesterolemia (HeFH). Top-line results from the Phase 2
studies for NASH and HeFH are expected by year-end and in the first
quarter of 2018, respectively.
Key findings from the long-term high fat diet (HFD) mouse NASH
model include:
- confirmation that prolonged treatment of mice with HFD
generates fatty liver disease with a liver gene array profile
consistent with activation of NASH inflammation and fibrosis
pathways
- findings that MGL-3196 potentially normalizes hepatic function
in HFD animals, including restoration of normal hepatic metabolic
regulation, liver size and histology without impacting tissues
outside the liver
- apparent reversal and prevention of the progression of lipid,
inflammatory and fibrotic markers of NASH at human equivalent
exposures of MGL-3196
Poster # 1969: MGL-3196, a β-Selective
Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic,
Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High
Fat Diet (HFD) Mouse NASH ModelRebecca Taub, John Franc, Martha
Kelly, Madrigal Pharmaceuticals, Villanova,
PAhttp://www.madrigalpharma.com/wp-content/uploads/2017/10/AASLD_poster_1969_final2.pdf
To view additional upcoming and archived events and
presentations, please go to
http://www.madrigalpharma.com/newsroom/presentations/
About Madrigal Pharmaceuticals Madrigal
Pharmaceuticals, Inc. (Nasdaq:MGDL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics that target a
specific thyroid hormone receptor pathway in the liver, which is a
key regulatory mechanism common to a spectrum of cardio-metabolic
and fatty liver diseases with high unmet medical need. The
Company’s lead candidate, MGL-3196, is a first-in- class, orally
administered, small-molecule, liver- directed, thyroid hormone
receptor (THR) β-selective agonist that is currently in Phase 2
development for NASH and heterozygous familial hypercholesterolemia
(HeFH). For more information, visit www.madrigalpharma.com.
Forward-Looking Statements This communication
contains “forward-looking statements” made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements reflect management's current
knowledge, assumptions, judgment and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct and
you should be aware that actual results could differ materially
from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the company's clinical
development of MGL-3196, the timing and outcomes of clinical
studies of MGL-3196, and the uncertainties inherent in clinical
testing. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Madrigal
undertakes no obligation to update any forward looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events. Please refer to Madrigal's filings with the U.S. Securities
and Exchange Commission for more detailed information regarding
these risks and uncertainties and other factors that may cause
actual results to differ materially from those expressed or
implied.
Investor Contact: Marc Schneebaum, Madrigal Pharmaceuticals,
Inc. IR@madrigalpharma.com
Media Contact: Mike Beyer, Sam Brown Inc. mikebeyer@sambrown.com
312-961-2502
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Sep 2023 to Sep 2024